ICON plc
ICON plc is a contract research organization that supports pharmaceutical, biotechnology, medical device, government, and public health clients across the drug and device development lifecycle. The company provides outsourced clinical development, consulting, commercialization, and post-marketing services from a global operating network centered in Dublin, Ireland.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueOutsourced planning, execution, and oversight of clinical trials and related development programs.
Advisory services spanning development planning, regulatory support, and commercialization strategy.
Services supporting approved products, including evidence generation and lifecycle studies.
Research and development services tailored to device and diagnostics clients.
Research and development support for public-sector and health-system clients.
Customers
ICON sells primarily to life sciences and healthcare organizations that outsource clinical research and development work. Its clients use ICON to access trial operations capability, specialized medical expertise, global site coverage, and program management capacity without building those functions internally.
Buy clinical development, trial management, and post-marketing support for large drug programs.
Buy outsourced development and consulting to advance pipeline assets efficiently.
Buy clinical and regulatory research services for devices and diagnostics.
Buy research and execution support for public health and policy-related studies.
Buy evidence generation and support services tied to product launch and lifecycle management.
Strategy
ICON’s strategy is centered on providing end-to-end outsourced development services across the full molecule-to-medicine journey. Its position depends on combining clinical operations scale with medical expertise, global site coverage, and integrated consulting capabilities for complex development programs.
Clients prefer providers that can support trials, consulting, and post-marketing work in one relationship.
Multi-country studies require local operational reach and consistent execution across regions.
Complex programs require deep medical and operational expertise to win and retain contracts.
Geography
2024ICON operates through a broad international network, with headquarters in Dublin and a presence in 55 countries across 97 locations. Revenue is generated globally and the company’s operating model depends on where work is performed, which creates meaningful exposure to multinational client spending, site access, and cross-border delivery.
Share of the revenue the company reports by geography.
Risks
ICON faces execution risk because its business depends on running complex, multi-site clinical programs on time and to protocol. It is also exposed to client concentration, regulatory change, and competitive pricing pressure common in outsourced research services, while its global structure adds foreign exchange and cross-border operating complexity.
- Clinical trial execution delaysImpact: HighLikelihood: High
The business depends on successful study delivery across many sites and geographies.
Exposure: Global trial operations
- Client budget cyclicalityImpact: HighLikelihood: Medium
Biopharma and device customers can defer outsourced research spending.
Exposure: Biotechnology and pharma demand
- Regulatory and compliance riskImpact: HighLikelihood: Medium
Clinical research must meet changing rules for ethics, data, and trial conduct.
Exposure: Multi-country operations
- Competitive pricing pressureImpact: MediumLikelihood: High
Large CRO contracts are competitive and may be awarded on price and capabilities.
Exposure: Outsourced research market
- Foreign exchange and transfer pricingImpact: MediumLikelihood: Medium
Revenue and costs are allocated across jurisdictions in a global contracting model.
Exposure: International structure
Accounting
Judgemental itemsClinical research services are delivered across reporting periods and revenue follows service progress.
Impact: Affects timing of revenue and margin recognition
Management must estimate stage of completion, costs to complete, and contract outcomes.
Impact: Can shift reported revenue and operating profit between periods
The group’s global contracting model allocates revenue and income across entities.
Impact: Affects where earnings are recorded and tax profile
Operations and contracts span many countries and currencies.
Impact: Can move reported revenue, assets, and expenses
Large acquired asset bases require periodic impairment testing.
Impact: May create non-cash charges if assumptions weaken
Similar listed companies
Publicly listed companies with a comparable business focus.
International Stem Cell CORP
ISCO · Pharmaceutical Preparations
Medtronic plc
MDT · Electromedical & Electrotherapeutic Apparatus
Medtronic plc designs, manufactures, and sells medical technologies used to diagnose, treat, and manage chronic and acute conditions across the body.
IR-Med, Inc.
Electromedical & Electrotherapeutic Apparatus
Icon Energy Corp
ICON · Deep Sea Foreign Transportation of Freight
Icon Energy Corp is a Marshall Islands-incorporated, Athens-based international shipping company that transports dry bulk cargoes on oceangoing vessels.
Davion Healthcare PLC
DAVI · Surgical & Medical Instruments & Apparatus
Davion Healthcare Plc is an Ireland-based healthcare company focused on developing and commercialising healthcare technologies and products.
AstraZeneca PLC
AZN · Pharmaceutical Preparations
AstraZeneca PLC is a global biopharmaceutical company focused on discovering, developing, and commercialising prescription medicines.
Last updated: 28/09/2026